James Paul Rickey Buys 27,777 Shares of Braveheart Bio (NASDAQ:BRVE) Stock

Braveheart Bio, Inc. (NASDAQ:BRVE) CFO James Paul Rickey purchased 27,777 shares of the firm’s stock in a transaction dated Friday, August 7th. The shares were bought at an average cost of $18.00 per share, with a total value of $499,986.00. Following the transaction, the chief financial officer directly owned 520,927 shares of the company’s stock, valued at approximately $9,376,686. This represents a 5.63% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Braveheart Bio Stock Performance

BRVE opened at $30.00 on Friday. Braveheart Bio, Inc. has a 12-month low of $28.47 and a 12-month high of $32.00.

About Braveheart Bio

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.